DZHK

MHADZHK

A key research focus at the DZHK partner site Munich is the identification of gene and environmental factors that are associated with cardiovascular disease. Here the aim is to identify molecular markers that predispose for the disease and its associated symptoms and, in conjunction with lifestyle factors, influence the development and course of the disease. More on: http://www.munich-heart-alliance.de  http://dzhk.de

Research Projects:

Translational Arrythmia Research Group

Duration: 2019 to 2020; Budget: € 208.000

PI: Stefan Kääb

Platelet Therapy Research Group

Duration: 2019 to 2020; Budget: € 479.000

PI: Steffen Massberg

Platelets are central mediators of arterial thrombosis and the main target of treatment as well as prophylaxis of coronary heart disease. However, despite improvements in antiplatelet therapy thrombotic disorders a still a leading cause of mortality worldwide. Therefore, the central aim of this project is to pave the way for innovative therapeutic approaches targeting the prothrombotic functions of platelets. This is based on an improved understanding of the interactions of platelets with the coagulation as well as the immune system using state-of-the-art basic science approaches and reaching to clinical evaluation. The results of this project will provide valuable insight into the mechanisms of thrombotic disorders and will break new ground for the treatment of coronary heart disease.

Gender Medicine

Duration: 2019 to 2020; Budget: € 208.000

PI: Julinda Mehili

gender-related analyses from different registries and ongoing randomized trials focused on clinical outcomes after trans-catheter aortic valve repair, after heart transplantation as well as after implantation of bioresorbable vascular scaffolds

Regulation of innate immune response in cardiovascular injury

Duration: 2019 to 2020; Budget: € 208.000

PI: Christian Schulz

Innate immune cells play a pivotal role in cardiovascular injury and inflammation. In this project, we aim to modulate innate immune responses in cardiovascular tissues to limit organ injury, improve repair processes and restore immune homeostasis. Specifically, we plan to target myeloid immune cells on the molecular and cellular level to alter their functions and regulate immune homeostasis. We thereby expect to identify novel therapeutic targets.

 

Preclinical Research:
   

PostDoc Start-up Grant: Role of oral FXa inhibitor on platelet function and arterial thrombosis

Duration: 2019; Budget: € 60.000

PI: Tobias Petzold

Recently approved new oral anticoagulants (NOACs) that comprise the direct oral factor Xa inhibitors (FXaI) and oral thrombin inhibitors (OTI) became an attractive alternative to vitamin-K antagonists for patients that require chronic anticoagulation for stroke prevention or treatment of thromboembolic disease. Results from large randomized clinical trials revealed that FXa inhibition with rivaroxaban reduces the frequency of myocardial infarction. Whether this clinical observed antithrombotic effect is due to an underlying molecular mechanism remains unknown. The central aim of our translational project is to investigate the role of FXa inhibition on platelet function and atherothrombosis and its underlying molecular mechanism. Our findings might help to better individualize anticoagulation therapies with NOACs in patients.

 

Clinical Studies:
 

APPROACH-ACS-AF-DZHK7: Apixaban versus Phenprocoumon: Orale Antikoagulation plus antithrombozytäre Therapie bei Patienten mit akuten Koronarsyndrom und Vorhofflimmern

ClinicalTrials.gov Identifier: NCT02789917

https://clinicaltrials.gov

Duration: 2016 to 2018; Budget: € 530.965,56

PI: Reza Wakili

SMART-MI-DZHK9: Implantierte Monitorinstrumente zur Überwachung von Hochrisikopatienten nach Herzinfarkt und reduzierter linksventrikulärer Auswurffraktion

ClinicalTrials.gov Identifier: NCT02594488

https://clinicaltrials.gov

Duration: 2016 to 2018; Budget: € 1.420.958,52

PI: Axel Bauer